Company has already identified ‘several acquisition targets’
International private client services provider Hawksford has secured a new majority investor.
European fund manager Star Capital Partnership will provide investment to drive the firm’s growth plans, with M&A being an integral part of Hawkford’s strategy.
The sum and majority shareholding were not revealed.
Strategy
Hawksford group chief executive Michel van Leeuwen said: “This deal is a significant vote of confidence in Hawksford’s strategy, management team, people, and ambition.
“Despite the global challenges defining 2020 and 2021, Star identified Hawksford as an attractive investment opportunity due to our stable and long-term client partnerships, sound business returns and potential for global growth. Several acquisition targets have been identified, which is why the partnership with Star represents an exciting step change in Hawksford’s successful evolution.”
Sarah Townsend
A company called Lakes BioScience has been granted planning permission to start preparatory work to build a biomanufacturing facility to produce medicines at a site in Cumbria.
South Lakeland Council awarded consent for groundworks to begin on the project, which would sit close to Glaxosmithkline’s current Ulverston factory on South Lonsdale Road, which the pharmaceutical giant expects to close over the next four years, it announced last week.
Lakes BioScience, formed from a team of UK industry experts, intends to build its plant on land owned by GSK and which GSK pledged to donate to the community for local economic development uses after ditching its own plans to build a new pharmaceutical factory on the site in 2017.
Plans to build a £350m biomanufacturing plant to produce modern medicines and boost the UK’s resilience have taken a major step forward. Lakes BioScience, formed from a team of UK industry experts, has been granted planning permission to start work on the site in Ulverston. The proposals will create 250.